RyghtSites.com Launches With a Bold Claim: Fixing a Broken Clinical Trial System
Ryght AI has introduced RyghtSites.com, a free platform that gives pharmaceutical companies and Contract Research Organizations (CROs) immediate access to a global database of clinical research sites. The company positions this tool as a direct response to one of the industry’s most persistent problems: slow and inefficient site selection.
The platform is powered by Ryght’s proprietary artificial intelligence system, which creates “AI Site Twins.” These are digital representations of real-world clinical trial sites, built from historical data, performance metrics, and trial experience.
The goal is simple. Replace months of manual research with instant, data-driven results.
The Industry Problem: Too Many Sites, Not Enough Clarity
Clinical trials are often delayed before they even begin. The issue is not a lack of sites. It is the opposite. Drug developers must sift through more than 100,000 potential research locations worldwide.
That sounds like a good problem to have. It is not.
Most teams rely on spreadsheets, outdated vendor databases, and internal guesswork. These methods can take three to six months just to produce a shortlist. By that time, timelines slip. Budgets stretch. Pressure builds.
Industry data shows that roughly 80% of clinical trials fail to meet enrollment deadlines. That number should raise eyebrows. It reflects a system that struggles at the starting line.
RyghtSites.com: A Search Engine Built for Clinical Trials
RyghtSites.com aims to remove that friction. The platform acts as a specialized search engine for clinical trial site selection.
Users enter trial criteria. This may include disease indication, biomarkers, geographic targets, and trial phase. The system then scans its network of AI Site Twins and produces a ranked list of sites based on real-world performance.
The process takes minutes, not months.
Key Capabilities That Stand Out
The platform introduces several features that reflect how modern data systems should operate.
Global Coverage
Users can search across more than 100,000 research sites in 192 countries. This level of coverage removes geographic blind spots and expands access to emerging markets.
Advanced Filtering
The system supports filtering by disease, biomarker, and related terms. It also allows sorting by region. This improves precision and reduces noise in search results.
Phase Compatibility
The platform supports Phase 1 through Phase 4 trials. This ensures that early-stage and late-stage studies can use the same tool without compromise.
Automated Ranking
The AI evaluates feasibility and fit. It ranks sites based on past performance and relevance to the trial criteria. This replaces subjective decision-making with data-backed scoring.
Exportable Data
Users can download results in CSV format. This allows integration with internal systems, reporting tools, and trial planning workflows.
Speed Is the Real Story Here
Speed is not just a feature. It is the headline.
Ryght points to a recent case study involving a global CRO. The organization reduced a six-month oncology site selection process to just 26 days. That is a dramatic shift. Even more interesting, the CRO exceeded its recruitment goal by 330%.
This is where the platform starts to feel less like a convenience and more like a necessity.
Time delays in clinical trials are not abstract problems. They translate into delayed treatments, increased costs, and missed opportunities. Every day matters.
Removing Cost Barriers From Critical Data
Another notable aspect of RyghtSites.com is its pricing model. It is free.
That decision stands out in an industry where data access often requires six-figure contracts. Many organizations, especially smaller biotech firms, struggle to justify those costs during early-stage planning.
By removing the paywall, Ryght shifts the conversation. Site selection data becomes accessible. It becomes usable. It becomes part of the standard workflow, not a premium add-on.
Leadership Perspective: A Smarter Starting Point
Simon Arkell, CEO and Co-Founder of Ryght AI, framed the launch as a practical fix to a long-standing issue.
He emphasized that traditional methods waste time and resources. His position is clear. Teams need a better starting point, one that relies on real data instead of outdated assumptions.
The platform uses the same AI infrastructure already deployed by enterprise clients. This is not a stripped-down version. It is the core system made publicly available.
Why This Matters for the Clinical Research Ecosystem
The launch of RyghtSites.com signals a shift in how clinical trial planning may operate moving forward.
It introduces three clear changes.
First, it compresses timelines. Second, it improves decision quality. Third, it lowers the barrier to entry for smaller organizations.
These changes do not just benefit sponsors and CROs. They affect patients waiting for new therapies. Faster trials can lead to faster approvals. Faster approvals can lead to faster access.
That is the ripple effect.
A Practical Shift in How Trials Begin
RyghtSites.com does not promise to fix every challenge in clinical research. It does address one of the most frustrating ones: figuring out where to run a trial.
It replaces guesswork with data. It replaces delay with speed. It replaces cost barriers with open access.
For an industry known for long timelines and heavy processes, that shift feels overdue.
Companies can access the platform today and run searches without cost. That alone makes it worth a look. If the results hold up at scale, this could become a standard tool in trial planning workflows rather than an optional add-on.